Raloxifene Hydrochloride

Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods).

General Details

Anti Estrogen Powder Keoxifene Raloxifene Hydrochloride CAS 82640-04-8 Powder Anti Cancer

 

Details:

 

English name: Raloxifene hydrochloride
English Synonyms: Raloxifene hydrochloride; Evista; Keoxifene hydrochloride; LY 156758; Raloxifene HCl;
CAS: 82640-04-8
Formula: C28H29NO4S
MW: 475.5992
Molecular Structure:

 

Raloxifene Hydrochloride Anti Estrogen Supplements 82640-04-8 Raloxifene HCL Anti Cancer Steroid
Density: 1.285g / cm3
Boiling point: 687.5 ° C at 760 mmHg
Flash Point: 369.6 ° C
Vapor Pressure: 1.56E-19mmHg at 25 ° C

Assay:99%

Appearance:light yellow powder

Use:antineoplastic

 

Specification:

 

ITEMS SPECIFICATION RESULT
Characters
Appearance White &off-white powder Conform
 

Solubility

Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water  

Conform

Identifications Infrared Absorption Conform
Chloride Conform
Tests

 

Loss on drying ≤0.5% 0.4%
Residue on ignition ≤0.1% 0.06%
Heavy metals ≤10ppm Conform
 

RRelated substances

 

Raloxifene Impurity1 ≤0.20 % 0.10%
Any unspecified individual impurity 2

 

≤0.10% Max. 0.08%
Total impurities ≤0.50% 0.40%
Assay Raloxifene HCl ≥98.0% 99.0%

 

Description:

 

Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).

 

(1) Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods). Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.
(2) Raloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.

 

Applications:
May prevent or treat corticosteroid-induced bone loss .American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.

 

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial).No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.

 

Use and Dose:
Evista is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women, the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. Evista is supplied as a 60 mg tablet designed for oral administration. The recommended initial dose of the drug is one 60 mg tablet daily, which may be administered any time of day without regard to meals.

 

Contact Now

  • 9 + 96 =
Order Enquiry

Contact Now

  • 3 + 76 =
Comments

Leave a Reply

Your email address will not be published. Required fields are marked *